Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Identification of predictive protein signatures of treatment-free remission in patients with chronic myeloid leukaemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJohn ColeRCRichard E. Clark

Discussion

Loading...

Member takes

Overview

Analysis reveals immune response and cytokine release patterns in chronic myeloid leukaemia patients, suggesting predictive biomarkers for treatment-free remission.

Key Points

  • Immune response shows key differences between molecular recurrence and treatment-free remission in CML patients.
  • Markedly altered cytokine release patterns were linked with treatment-free remission outcomes in the study.
  • Analysis involving bone marrow proteomic profiles utilized mass spectrometry and RNA-sequencing for deeper understanding.
  • Findings emphasize the potential of identifying biomarkers associated with chronic myeloid leukaemia recovery phases.

Cite This Study

Cole et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd60https://doi.org/10.1182/blood-2025-1992
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Intronic DNA variants in EZH2 and GATA2 predict treatment-free remission in chronic myeloid leukemia patients from the destiny trial2025
  2. 2BCR::ABL1 evaluation in bone marrow is no more predictive of TFR success than from peripheral blood2025
  3. 3A single-cell atlas of diagnostic bone marrow to uncover the origins of CML relapse following therapy cessation2025
  4. 4Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study2026 · 1 citations
  5. 5Gene expression analysis of patients with chronic myeloid leukemia who discontinued tyrosine kinase inhibitor2025